Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025
Annovis Bio Inc. will present significant advancements in Alzheimer’s treatment at the Alzheimer’s Association International Conference 2025, highlighting the potential of its lead candidate, buntanetap.
Annovis Bio Inc. (NYSE: ANVS), a company at the forefront of developing therapies for neurodegenerative diseases, is set to participate in the Alzheimer’s Association International Conference (AAIC) from July 27–31, 2025, in Toronto. The conference will serve as a platform for Annovis Bio to unveil four scientific posters, showcasing the progress of its Alzheimer’s clinical program and pharmacokinetic data related to buntanetap, its leading drug candidate.
The presentations will cover a range of critical topics, including the design of a Phase III clinical trial, efficacy and safety data from previous studies, and comparative pharmacokinetics of various drug formulations tested in both animal and human subjects. These findings are pivotal as they underscore the potential of buntanetap to address the complex challenges of Alzheimer’s disease, offering hope for improved treatment options.
For further details on Annovis Bio’s participation and the data to be presented, interested parties can view the full press release here.